Does Teladoc's $65 Million Acquisition of Catapult Health Make the Stock a Buy?
Telemedicine specialist Teladoc Health (TDOC 1.53%) has been a terrible investment over the past three years. Once the company's pandemic-fueled business boom cooled down, its revenue and visit growth slowed down considerably while it remained unprofitable.
Teladoc Expands Specialty Care Access With Carrum Health Partnership
TDOC partners with Carrum Health in a bid to expand access to specialty care.
Teladoc Doubles Down on Connected Care With New Partnerships
With more than 93 million members, deeper integration of services could lead to higher utilization for TDOC.
Teladoc (TDOC) Advances While Market Declines: Some Information for Investors
Teladoc (TDOC) closed at $9 in the latest trading session, marking a +0.78% move from the prior day.
Teladoc Boosts Weight Care Access With LillyDirect, Aids Growth
TDOC expands weight care access with LillyDirect, boosting growth by offering affordable GLP-1 medications like Zepbound, enhancing patient outcomes and engagement.
Teladoc Health Enhances Prism Platform for Better Virtual Care
TDOC upgrades its Prism platform with AI-powered tools, improved referrals and data integration, enhancing care coordination to bolster its member base.
Teladoc Health, Inc. (TDOC) TD Cowen 45th Annual Health Care Conference (Transcript)
Teladoc Health, Inc. (NYSE:TDOC ) TD Cowen 45th Annual Health Care Results Conference March 3, 2025 10:30 AM ET Company Participants Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Charles Rhyee Thank you everyone for being here for the next session here. We're pleased to have Teladoc Health with us today.
Why Teladoc Stock Is Plummeting Today
Teladoc (TDOC -11.83%) stock is sinking in Thursday's trading on the heels of the company's recent fourth-quarter release. The telehealth specialist's share price was down 11.7% as of 2:45 p.m.
Teladoc Q4 Earnings: A Waiting Game For Investors (Rating Downgrade)
Teladoc Health, Inc.'s disappointing guidance and lack of revenue growth have led me to adopt a neutral stance on TDOC stock despite its cheap valuation at 7x forward free cash flow. My investment strategy focuses on businesses with strong balance sheets and the potential for significant free cash flow growth, but Teladoc's fundamentals don't align with this narrative. Teladoc's manageable debt and plans to retire convertible debt improve its financial footing, but I need to see revenue momentum before considering it investable again.
Teladoc Health, Inc. (TDOC) Q4 2024 Earnings Call Transcript
Teladoc Health, Inc. (NYSE:TDOC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Michael Minchak - Head of Investor Relations Chuck Divita - Chief Executive Officer Mala Murthy - Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Jessica Tassan - Piper Sandler David Roman - Goldman Sachs Sean Dodge - RBC Richard Close - Cannacord Genuity Daniel Grosslight - Citi Jailendra Singh - Truist George Hill - Deutsche Bank Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Operator Good afternoon and thank you all for attending the Teladoc Health Q4 2024 Earnings Call.
Here's What Key Metrics Tell Us About Teladoc (TDOC) Q4 Earnings
While the top- and bottom-line numbers for Teladoc (TDOC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teladoc (TDOC) Reports Q4 Loss, Tops Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.17 per share a year ago.
